Evidence map›Paper›PMID 36177041›Full record

ReviewFrontiers in immunology2022

Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.

Hui Xu, Chenxi Cao, Yuqing Ren, Siyuan Weng, Long Liu, Chunguang Guo, Libo Wang, Xinwei Han, Jianzhuang Ren, Zaoqu Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 99 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hui XuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chenxi CaoDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuqing RenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Siyuan WengDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Long LiuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunguang GuoDepartment of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Libo WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinwei HanDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jianzhuang RenDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zaoqu LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fecal microbiome transplantation (FMT) from healthy donors is one of the techniques for restoration of the dysbiotic gut, which is increasingly being used to treat various diseases. Notably, mounting evidence in recent years revealed that FMT has made a breakthrough in the oncology treatment area, especially by improving immunotherapy efficacy to achieve antitumor effects. However, the mechanism of FMT in enhancing antitumor effects of immune checkpoint blockers (ICBs) has not yet been fully elucidated. This review systematically summarizes the role of microbes and their metabolites in the regulation of tumor immunity. We highlight the mechanism of action of FMT in the treatment of refractory tumors as well as in improving the efficacy of immunotherapy. Furthermore, we summarize ongoing clinical trials combining FMT with immunotherapy and further focus on refined protocols for the practice of FMT in cancer treatment, which could guide future directions and priorities of FMT scientific development.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaNeoplasmsDysbiosisFecal Microbiota TransplantationHumansImmune Checkpoint InhibitorsImmune Checkpoint Inhibitorscancerfecal microbiota transplantationFMTgut microbiotaimmunotherapy

Identifiers

PMID36177041
PMCPMC9513044
OpenAlexW4295749214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.